The FDA has made some modest efforts, but it needs an internal organization that understands and would be an aggressive ...

P-gp and BCRP Substrates: Avoid concomitant use of sensitive substrates of P-gp and BCRP with FILSPARI. Sparsentan may increase exposure of these transporter substrates, which may increase the risk of ...

Pursuing dangerous Medicaid block grant schemes and allowing flagrant violations of unequivocal state laws looks like ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, discusses recent advancements in the treatment of brain tumors.

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...